AFP联合CA199检测对原发性肝癌的诊断价值及对三维适形放疗的疗效判断

Dynamic Measurement of Serum AFP and CA199 Contents for Diagnosis and Assessment of Efficacy of Local Radiotherapy in Patients with Primary Liver Cancer

目的:通过联合检测血清中AFP及CA199的含量,观察其对原发性肝癌(PLC)的临床诊断及疗效观察的价值。方法:85例PLC患者、42例肝良性疾病患者血清样品用电化学发光免疫法测定AFP及CA199的含量。结果:与良性肝病相比,PLC患者血清AFP及CA199含量明显升高(P(0.01),两项标志物阳性检出率分别为81.2%和53.0%,两者联检阳性率为88.8%。PLC患者血清AFP、CA199含量在治疗后与治疗前相比,有显著性差异(P(0.05)。结论:AFP及CA199测定对肝肿瘤的良恶性辅助诊断具有一定的应用价值,联检不仅可以提高PLC的阳性诊断率,对PLC的三维适形疗效监测也具有重要价值。

Objective To investigate the usefulness of dynamic combined measurement of serum AFP and CA199 contents in diagnosis and treatment efficacy assessment in patients with primary liver carcinoma. Methods Serum AFP and CA199 contents were measured with CLIA in 85 patients with primary liver cancer both before and after 3 - dimensional conformal local radiotherapy, 42 patients with benign hepatic disorders and 52 controls. Results Serum AFP and CA199 contents in patients with primary hepatic cancer were significantly higher than those in patients with benign hepatic disorders and controls （ P 〈 0.01 ）. The diagnostic sensitivity of AFP and CA199 for liver cancer was 81.2% and 53.0% respectively, with 88.8% for combined determination of the two markers. In the cancer patients, the concentrations of the markers dropped significantly after radiotherapy （P 〈 0.05 ）. Conclusion Combined determination of serum AFP and CA199 contents would increase the diagnostic senitivity for primary liver cancer and was also valuable for assessment of the therapeatic result of local radiotherapy.